Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL
Details : Epinephrine Injection is indicated for emergency treatment of allergic reactions (Type I), including anaphylaxis, which may result from insect stings or bites, foods, drugs and other allergens.
Product Name : Epinephrine-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
October 29, 2024
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Disodium Hydrogen Phosphate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and "AP" Rated¹
Details : Sodium Phosphate is an approved small molecule, indicated as a source of phosphorous, for addition to large volume IV fluids, to prevent hypophosphatemia in patients with restricted or no oral intake.
Product Name : Sodium Phosphate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Disodium Hydrogen Phosphate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹
Details : Potassium Phosphates intravenous injection is a phosphorus replacement product indicated as a source of phosphorus, which is indicated for s to correct hypophosphatemia in adults and pediatric patients 12 years of age and older.
Product Name : Potassium Phosphate-Geneic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane, which is indicated in the treatment of primary systemic carnitine deficiency.
Product Name : Carnitor-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2023
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
Details : Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.
Product Name : Injectafer
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
August 26, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Introduces FDA-Approved Epinephrine Injection, USP
Details : Epinephrine is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Product Name : Epinephrine-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paclitaxel protein-bound particles for injectable suspension is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. It is indicated for metastatic breast cance...
Product Name : Paclitaxel-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 05, 2023
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches Paclitaxel Protein-Bound Particles Injectable Suspension
Details : Paclitaxel protein-bound particles is a microtubule inhibitor indicated for metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer & metastatic pancreatic adenocarcinoma.
Product Name : Paclitaxel-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 05, 2023
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches FDA-Approved Atropine Sulfate Injection, USP
Details : Atropine Sulfate Injection inhibits the muscarinic actions of acetylcholine, which is indicated for temporary blockade of severe or life-threatening muscarinic effects and to treat bradyasystolic cardiac arrest.
Product Name : Atropine Sulfate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Provepharm Life Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
American Regent Launches a New Vial Presentation
Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.
Product Name : ProvayBlue
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Provepharm Life Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable